Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9978410.26442/20751753.2022.8.201721Research ArticleDermatofibrosarcoma protuberans in dermatological practice. Case reportKatinaMaryia A.<p>Cand. Sci. (Med.)</p>vitebsk-derma@mail.ruLesnichayaOlesya V.<p>Cand. Sci. (Med.)</p>5114528@rambler.ruRyazanovaNatalya V.<p>Head of Day Care Deparment</p>vokvd@vitebsk.byVitebsk State Medical UniversityVitebsk Regional Clinical Center of Dermatovenereology and Cosmetology020820222485235282901202226072022Copyright © 2022, Consilium Medicum2022<p>Dermatofibrosarcoma protuberans (DFSP) is a mesenchymal neoplasm of fibrohistiocytic origin of moderate malignancy. The pathogenesis of DFSP involves chromosomal translocation, which leads to the formation of a fusion protein that promotes tumor growth due to increased production of platelet growth factor (PDGF). Clinically, it begins with an asymptomatic fibrous papule or firm plaques, which gradually over the course of several years become enlarged with the formation of asymmetrical multi-nodular structure of purple or red-brown color. The standards of diagnosis is a histological examination with the detection of a poor limited infiltrate indermis of a storiform architecture consisting of monomorphic spindle cells and diffuse CD34+ staining during immunohistochemistry. Complete surgical excision is considered the gold standard of treatment. Clinical case: female patient, 35 years old with a lesion in the form of a dense plaque in right subclavian area was examined by a dermatologist. The primary diagnosis was made as "morphea". In a year a slight growth of the lesion and the appearance of small firm nodules asymmetrically along the periphery were noted. According to the results of histological and immunohistochemistry studies the diagnosis of DFSP was made, the patient was referred to an oncologist for complete tumor removal.</p>dermatofibrosarcoma protuberansDFSPCD34+histologyspindle cellsдерматофибросаркома выбухающаяDFSPCD34+гистологическое исследованиеверетенообразные клетки[Brooks J, Ramsey ML. Dermatofibrosarcoma Protuberans. Available at: http://www.ncbi.nlm.nih.gov/books/NBK513305/. Accessed: 08.08.2022.][Hornick JL. Cutaneous soft tissue tumors: how do we make sense of fibrous and “fibrohistiocytic” tumors with confusing names and similar appearances? Modern Pathology. 2020;33:56-65. DOI:10.1038/s41379-019-0388-4][Theosetal AJ. Pediatric dermatology. Elsevier Mosby, 2005.][Hao Х, Billings SD, Wu F, et al. Dermatofibrosarcoma protuberans: update on the diagnosis and treatment. J Clin Med. 2020;9(1752):22. DOI:10.3390/jcm9061752][Abbott JJ, Oliveira AM, Nascimento AG. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol. 2006;30(4):436-43. DOI:10.1097/00000478-200604000-00002][Beaziz J, Battistella M, Delyon J, et al. Long-term outcome of neoadjuvant tyrosine kinase inhibitors followed by complete surgery in locally advanced dermatofibrosarcoma protuberans. Cancers (Basel). 2021;13(9):2224. DOI:10.3390/cancers130922242][Calonje E, Brenn T, McKee PH. Мckee`s pathology of the skin. Elsevier Saunders, 2011.][Patterson JW. Weedon`s Skin Pathology. Elsevier Limited, 2016.][Lyu A, Wang Q. Dermatofibrosarcoma protuberans: a clinical analysis. Oncol Lett. 2018:16(2):1855-62. DOI:10.3892/ol.2018.8802][Hugel H. Fibrohistiocytic skin tumors. JDDG. 2006;4(7):544-54. DOI:10.1111/j.1610-0387.2006.06021.x][Dimitropoulos VA. Dermatofibrosarcoma protuberans. Dermatol Ther. 2008;21(6):428-32.][Serra-Guillén C, Llombart B, Sanmartín O. Dermatofibrosarcoma protuberans. Actas Dermosifiliogr. 2012;103(9):762-77. DOI:10.1016/j.ad.2011.10.007][Riggs K, McGuigan KL, Morrison WB, et al. Role of magnetic resonance imaging in perioperative assessment of dermatofibrosarcoma protuberans. Dermatol Surg. 2009:35(12):2036-41. DOI:10.1111/j.1524-4725.2009.01330.x][Foot O, Hallin M, Bagué S, et al. Superficial CD34-positive fibroblastic tumor. Int J Surg Pathol. 2020;28(8):879-81. DOI:10.1177/1066896920938133][Mao Xu, Ying-Ying Sun, Ming-Liang D, et al. Superficial CD34-positive fibroblastic tumor: report of two cases and review of literature. Int J Clin Exp Pathol. 2020;13(1):38-43.][Lao IW, Yu L, Wang J. Superficial CD34-positive fibroblastic tumour: a clinicopathological and immunohistochemical study of an additional series. Histopathology. 2017;70:394-401. DOI:10.1111/his.13088][Mutgi KAJ, Chitgopeker P, Ciliberto H, Stone MS. Hypocellular plaque-like CD34-positive dermal fibroma (medallion-like dermal dendrocyte hamartoma) presenting as a skin-colored dermal nodule. Pediatr Dermatol. 2016;33(1):e16-9. DOI:10.1111/pde.12726][Galimberti G, Montaño AP, Kowalczuk A, et al. Outcomes in 11 patients with dermatofibrosarcoma protuberans treated with Mohs micrographic surgery. Int J Dermatol. 2011;51(1):89-93. DOI:10.1111/j.1365-4632.2010.04721.x][Lee SH, Oh Y, Nam KA, et al. Mohs micrographic surgery for dermatofibrosarcoma protuberans: comparison of frozen and paraffin techniques. J Eur Acad Dermatology Venereol. 2018;32(12):2171-7. DOI:10.1111/jdv.15201][Paradisi A, Abeni D, Rusciani A, et al. Dermatofibrosarcoma protuberans: Wide local excision vs. Mohs micrographic surgery. Cancer Treatment Reviews. 2008;34(8):728-36. DOI:10.1016/j.ctrv.2008.06.002][McArthur GA, Demetri GD, Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23(4):866-73. DOI:10.1200/JCO.2005.07.088][Navarrete-Dechent C, Mori S, Barker CA, et al. Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans. JAMA Dermatology. 2019;155(3):361-9. DOI:10.1001/jamadermatol.2018.494]